Regressive changes in finasteride-treated human hyperplastic prostates correlate with an upregulation of TGF-β receptor expression

Prostate

Volumn 37, Issue 2, 1998, Pages 84-90

  Sáez, Carmen ^a   González Baena, Antonio C ^a,c   Japón, Miguel A ^a   Giráldez, Javier ^a   Segura, Dolores I ^a   Miranda, Gonzalo ^a   Rodríguez Vallejo, José M ^b   González Esteban, Jorge ^b   Torrubia, Francisco ^a  

^a HOSPITAL UNIVERSITARIO VIRGEN DEL ROCÍO   (Spain)

^b Medical affairs Merck sharp and Dohme ltd   (Spain)

^c HOSPITAL JUAN RAMÓN JIMÉNEZ   (Spain)

Author keywords

Benign prostatic hyperplasia; Finasteride; Prostate; TGF ; TGF receptors

Indexed keywords

FINASTERIDE; MESSENGER RNA; PROSTATE SPECIFIC ANTIGEN; TRANSFORMING GROWTH FACTOR BETA RECEPTOR;

APOPTOSIS; ARTICLE; CELLULAR DISTRIBUTION; CLINICAL ARTICLE; CONTROLLED STUDY; HISTOLOGY; HUMAN; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; MALE; PRIORITY JOURNAL; PROSTATE EPITHELIUM; PROSTATE HYPERTROPHY; PROSTATECTOMY; RECEPTOR UPREGULATION;

APOPTOSIS; ATROPHY; ENZYME INHIBITORS; FINASTERIDE; HUMANS; MALE; PROSTATE; PROSTATIC HYPERPLASIA; RECEPTORS, TRANSFORMING GROWTH FACTOR BETA; UP-REGULATION;

EID: 0031658193     PISSN: 02704137     EISSN: None     Source Type: Journal    
DOI: 10.1002/(SICI)1097-0045(19981001)37:2<84::AID-PROS4>3.0.CO;2-L     Document Type: Article

References (31)

1. Schröder FH: 5α-reductase inhibitors and prostatic disease. Clin Endocrinol (Oxf) 1994;41:139-147.
2. Geller J: Effect of finasteride, a 5α-reductase inhibitor on prostate tissue androgens and prostate-specific antigen. J Clin Endocrinol Metab 1990;71:1552-1555.
3. McConnell JD, Wilson JD, George FW, Geller J, Pappas F, Stoner E: Finasteride, an inhibitor of 5α-reductase, suppresses prostatic dihydrotestosterone in men with benign prostatic hyperplasia. J Clin Endocrinol Metab 1992;74:505-508.
4. Stoner E, Finasteride Study Group: Three year safety and efficiency data on the use of finasteride in the treatment of benign prostatic hyperplasia. Urology 1994;43:284-294.
5. Finasteride Study Group: Finasteride (MK-906) in the treatment of benign prostatic hyperplasia. Prostate 1993;22:291-299.
6. Boyle P, Gould L, Roehrborn CG: Prostate volume predicts outcome of treatment of benign prostatic hyperplasia with finasteride: Meta-analysis of randomized clinical trials. Urology 1996; 48:398-405.
7. Rittmaster RS, Norman RW, Thomas LN, Rowden G: Evidence for atrophy and apoptosis in the prostates of men given finasteride. J Clin Endocrinol Metab 1996;81:814-819.
8. Rittmaster RS, Manning AP, Wright AS, Thomas LN, Whitefield S, Norman RW, Lazier CB, Rowden G: Evidence for atrophy and apoptosis in the ventral prostate of rats given the 5α-reductase inhibitor finasteride. Endocrinology 1995;136:741-748.
9. Laroque PA, Prahalada S, Molon-Nablot S, Cohen SM, Soper K, Duprat P, Peter CP, van Zwieten MJ: Quantitative evaluation of glandular and stromal compartments in hyperplastic dog prostates: Effect of 5-alpha reductase inhibitors. Prostate 1995;27: 121-128.
10. Steiner MS: Review of peptide growth factors in benign prostatic hyperplasia and urological malignancy. J Urol 1995;153: 1085-1096.
11. Culig Z, Hobisch A, Cronauer MV, Radmayr C, Hittmair A, Zhang J, Thurnher M, Bartsch G, Klocker H: Regulation of prostatic growth and function by peptide growth factors. Prostate 1996;28:392-405.
12. Massagué J: The transforming growth factor-β family. Annu Rev Cell Biol 1990;6:597-641.
13. Mori H, Maki M, Oishi K, Jaye M, Igarashi K, Yoshida O, Hatanaka M: Increased expression of genes for basic fibroblast growth factor and transforming growth factor type β2 in human benign prostatic hyperplasia. Prostate 1990;16:71-80.
14. Kyprianou N, Isaacs JT: Expression of transforming growth factor-β in the rat ventral prostate during castration-induced programmed cell death. Mol Endocrinol 1989;3:1515-1522.
15. Sutkowski DM, Fong CJ, Sensibar JA, Rademaker AW, Sherwood ER, Kozlowski JM, Lee C: Interaction of epidermal growth factor and transforming growth factor beta in human prostatic epithelial cells in culture. Prostate 1992;21:133-143.
16. Massagué J: Receptors for the TGF-β family. Cell 1992;69:1067-1070.
17. Wrana JL, Attisano L, Wieser R, Ventura F, Massagué J: Mechanism of activation of the TGF-β receptor. Nature 1994;370:341-347.
18. Kim IY, Ahn HJ, Zelner DJ, Park L, Sensibar JA, Lee C: Expression and localization of transforming growth factor-β receptors type I and type II in the rat ventral prostate during regression. Mol Endocrinol 1996;10:107-115.
19. Barry MJ, Fowler FJ Jr, O'Leary MP, Bruskewitz RC, Holtgrewe HL, Mebust WK, Cockett ATK, Measurement Committee of the American Urological Association: The American Urological Association Symptom Index for benign prostatic hyperplasia. J Urol 1992;148:1549-1557.
20. Lin HY, Wang XF, Ng-Eaton E, Weinberg RA, Lodish HF: Expression cloning of the TGF-β type II receptor, a functional transmembrane serine/threonine kinase. Cell 1992;68:775-785.
21. Harada M, Kinoshita Y, Moriyama M, Kondo I, Nakahashi M, Kumagai H, Sasaki K, Hosaka M: Histological evaluation of benign prostatic hyperplasia treated by long-term administration of chlormadinone acetate (CMA). Prostate 1994;25:147-155.
22. English HF, Kyprianou N, Isaacs JT: Relationship between DNA fragmentation and apoptosis in the programmed cell death in the rat ventral prostate following castration. Prostate 1989;15: 233-251.
23. Coffey DS, Walsh PC: Clinical and experimental studies of benign prostatic hyperplasia. Urol Clin North Am 1990;17:461-475.
24. Kyprianou N, Isaacs JT: Activation of programmed cell death in the rat ventral prostate after castration. Endocrinology 1988;122: 552-562.
25. Banerjee PP, Banerjee S, Tilly KI, Tilly JL, Brown TR, Zirkin BR: Lobe-specific apoptotic cell death in rat prostate after androgen ablation by castration. Endocrinology 1995;136:4368-4376.
26. Rotello R, Lieberman R, Purchio A, Gerschenson L: Coordinated regulation of apoptosis and cell proliferation by transforming growth factor β1 in cultured uterine epithelial cells. Proc Natl Acad Sci USA 1991;88:3412-3415.
27. Yanagihara K, Tsumuraya M: Transforming growth factor β1 induces apoptotic cell death in cultured human gastric carcinoma cells. Cancer Res 1992;52:4042-4045.
28. Wang CY, Eshleman JR, Wilson JKV, Markowitz S: Both transforming growth factor-β and substrate release are inducers of apoptosis in a human colon adenoma cell line. Cancer Res 1995; 55:5101-5105.
29. Kyprianou N, Huacheng T, Jacobs SC: Apoptotic versus proliferative activities in human benign prostatic hyperplasia. Hum Pathol 1996;27:668-675.
30. Eklöv S, Funa K, Nordgren H, Olofsson A, Kanzaki T, Miyazono K, Nilsson S: Lack of the latent transforming growth factor β binding protein in malignant, but not benign prostatic tissue. Cancer Res 1993;53:3193-3197.
31. Story MT, Hopp KA, Meier DA, Begun FP, Lawson RK: Influence of transforming growth factor β1 and other growth factors on basic fibroblast growth factor level and proliferation of cultured human prostate-derived fibroblasts. Prostate 1993;22: 183-197.